The product “met all four pre-specified primary endpoints (fusion rate, NDI score, neurological outcomes, and safety success), demonstrating non-inferiority to autograft with p-values of < 0.0005 for each.
IFACTOR WORKBOOK TRIAL
The company provided data to the FDA from a pivotal clinical trial comparing i-Factor to autograft in ACDF procedures. “This unique combination replicates the organic (Type I human collagen) and inorganic (calcium phosphate) components of autograft bone and creates the ideal template for new bone formation.”
It can be used as a substitute for autologous bone in ACDF procedures.Īccording to the company, i-Factor is the only biologic bone graft that combines the small P-15 peptide with anorganic bone mineral (ABM). I-Factor is a bone graft based on synthetic small peptide (P-15) technology developed by the company to support bone growth through cell attachment and activation. The PMA approval came pretty quickly as the company only submitted its PMA application in September 2014. In fact, the cooperation was so good that the FDA didn't even require a meeting of its orthopedic panel of experts to weigh in on whether or not the agency should approve the product. He called the process with the FDA "years of seamless cooperation" with the company's clinical investigators. The first was Medtronic plc's Infuse, which was approved for use for the lumbar region of the spine back in 2004.Ĭompany President and COO Jeffrey Marx, Ph.D., said this was "an historic milestone" for the surgical treatment of cervical disc degeneration. This is the first bone graft to be approved for use in the cervical spine and only the second PMA-approved bone graft in the spine.
announced the agency approved their i-Factor Peptide Enhance Bone Graft for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative disc disease. It's been a long, long time since the FDA gave their PMA (Premarket Approval) application blessing to bone graft for the spine.īut on November 3, 2015, Cerapedics, Inc.
0 kommentar(er)
